Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndroms

Medical Science Monitor

Volumn 6, Issue 4, 2000, Pages 684-691

  Rość, Danuta ^a   Kremplewska Nalezyta, Elzbieta ^a   Gadomska, Grazyna ^b   Zastawna, Ewa ^a   Michalski, Arkadiusz ^a   Drewniak, Wanda ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Wojewodzki Szpital im Dr J Biziela w Bydgoszczy   (Poland)

Author keywords

Myeloproliferative syndromes; Plasminogen activator inhibitors; Plasminogen activators

Indexed keywords

FIBRINOGEN DEGRADATION PRODUCT; LEUKOCYTE ELASTASE; PLASMIN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; TISSUE PLASMINOGEN ACTIVATOR; TRYPSIN INHIBITOR; UROKINASE;

ADULT; AGED; ARTICLE; BLEEDING TENDENCY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; THROMBOCYTHEMIA; THROMBOSIS;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; THROMBOCYTHEMIA, HEMORRHAGIC; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033856583     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Przewlekle zespoly mieloproliferacyjne
2. Zespol mieloproliferacyjny (z. m-p)
3. Histological and cytological typing of neoplastic diseases of haemopoetic and lymphoid tissues. WHO International Histological Classification of Tumors. WHO, Genewa
4. Tumor interactions with the vasculature angiogenesis and tumor metastasis
5. Tissue inhibitor of metallo-proteinases (TIMP, aka, EPA): Structure, control of expansion and biological functions
6. Activation of coagulation and fibrinolysis in patients with lung cancer relation to tumor stage and prognosis
7. Increase in levels of plasminogen activator and type 1 plasminogen activator inhibitor in human breast cancer. Possible role in tumor progression and metastasis
8. Postepy w diagnostyce wewnaqtrznaczyniowej aktywacji fibrynolizy
9. Increase in the D-dimer levels treatment in patients with acute myelogeneous leukemia
10. The influence of induction chemotherapy and remission. Status of haemostasis in patients treated for acute myeloid leukaemia
11. Haemostatic changes in patients with acute lymphoblastic leukaemia during and after remission induction therapy
12. High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocytemia are associated with thrombi
13. Fibrinolytic imbalance in essential thrombocytopenia. Role of platelets
14. Prognostic value of plasminogen activators and their inhibitors in colorectal cancer
15. Fibrinolytic system in plasma and pleural fluid in malignant. Pleural mesothelioma
16. Plasma urokinase-type plasminogen activator in patients with leukemias
17. The physiological aspects of fibrinolysis
18. Cellular receptors for the plasminogen activators
19. The urokinase receptor (CD 87) is expressed in cells of the magekarioblastic lineage
20. Enhanced activation of prourokinase by human RC 2A leukemia cells
21. Tissue factor (TF) and urokinase plasminogen activator receptor(u-PAR) and bleeding complications in leukemic patients
22. Role of neutrophil membrane proteases in fibrin degradation
23. Procoagulant activity of mononuclear cells is increased in myeloproliferative and myelodysplastic diseases
24. Effect of the plasminogen activator inhibitor on human leucocyte elastase
25. The cleavage and inactivation of plasminogen activator inhibitor type 1 by neutrophil elastase: The evaluation of its plasminogen relevance in fibrinolysis
26. Postepy wiedzy o regulacji fibrynolizy
27. Poteins of the fibrinolytic system in human thrombi
28. Plasminogen activator inhibitor-2 in patients with monocytic leukemia
29. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination
30. Plasminogen activator inhibitors in endometrial adenocarcinoma
31. Occurrence of the specific plasminogen activator inhibitor of placental type, PAI-2 in ascitic fluid and tumor vessel blood from patients with ovarian carcinoma